WO2005124357A1 - Utilisation de la proteine facteur d'elongation 1-alpha-1 comme marqueur pour le cancer du sein - Google Patents

Utilisation de la proteine facteur d'elongation 1-alpha-1 comme marqueur pour le cancer du sein Download PDF

Info

Publication number
WO2005124357A1
WO2005124357A1 PCT/EP2005/006530 EP2005006530W WO2005124357A1 WO 2005124357 A1 WO2005124357 A1 WO 2005124357A1 EP 2005006530 W EP2005006530 W EP 2005006530W WO 2005124357 A1 WO2005124357 A1 WO 2005124357A1
Authority
WO
WIPO (PCT)
Prior art keywords
marker
efll
breast cancer
sample
protein
Prior art date
Application number
PCT/EP2005/006530
Other languages
English (en)
Inventor
Gabriele Pestlin
Herbert Andres
Peter Berndt
Marie-Luise Hagmann
Johann Karl
Hanno Langen
Michael Thierolf
Werner Zolg
Original Assignee
Roche Diagnostics Gmbh
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, F.Hoffmann-La Roche Ag filed Critical Roche Diagnostics Gmbh
Publication of WO2005124357A1 publication Critical patent/WO2005124357A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le diagnostic du cancer du sein, l'utilisation de la protéine EF1A1 (facteur d'élongation 1A1) dans le diagnostic du cancer du sein ainsi qu'une méthode de diagnostic du cancer du sein à partir d'un échantillon liquide prélevé sur un individu, laquelle méthode consiste à mesurer la EF1A1 dans cet échantillon. La mesure de la EF1A1 peut, p. ex., être utilisée dans le diagnostic ou le dépistage précoce du cancer du sein.
PCT/EP2005/006530 2004-06-18 2005-06-17 Utilisation de la proteine facteur d'elongation 1-alpha-1 comme marqueur pour le cancer du sein WO2005124357A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04014316 2004-06-18
EP04014316.6 2004-06-18

Publications (1)

Publication Number Publication Date
WO2005124357A1 true WO2005124357A1 (fr) 2005-12-29

Family

ID=34970268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006530 WO2005124357A1 (fr) 2004-06-18 2005-06-17 Utilisation de la proteine facteur d'elongation 1-alpha-1 comme marqueur pour le cancer du sein

Country Status (1)

Country Link
WO (1) WO2005124357A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077176A2 (fr) * 2001-03-22 2002-10-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Proteines presentant une expression aberrante dans des tumeurs microdissequees capturees au laser
US20030064419A1 (en) * 2000-03-20 2003-04-03 Chandrasiri Herath Herath Mudiyanselage Athula Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003087831A2 (fr) * 2002-04-11 2003-10-23 Oxford Glycosciences (Uk) Ltd Proteines impliquees dans le cancer du sein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064419A1 (en) * 2000-03-20 2003-04-03 Chandrasiri Herath Herath Mudiyanselage Athula Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002077176A2 (fr) * 2001-03-22 2002-10-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Proteines presentant une expression aberrante dans des tumeurs microdissequees capturees au laser
WO2003087831A2 (fr) * 2002-04-11 2003-10-23 Oxford Glycosciences (Uk) Ltd Proteines impliquees dans le cancer du sein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRANDS J H G M ET AL: "THE PRIMARY STRUCTURE OF THE ALPHA SUBUNIT OF HUMAN ELONGATION FACTOR 1 STRUCTURAL ASPECTS OF GUANINE-NUCLEOTIDE-BINDING SITES", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 155, no. 1, 1 February 1986 (1986-02-01), pages 167 - 171, XP000612183, ISSN: 0014-2956 *
DATABASE UniProt [online] 13 August 1987 (1987-08-13), "Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) (Elongation factor Tu) (EF-Tu).", XP002345218, retrieved from EBI accession no. UNIPROT:P68104 Database accession no. P68104 *

Similar Documents

Publication Publication Date Title
EP2401621B1 (fr) Utilisation de s-erbb-3 comme marqueur des cancers
US7566542B2 (en) Use of protein ASC as a marker for breast cancer
US20070196844A1 (en) Protein PDX1 as a marker for breast cancer
US7579158B2 (en) Cellular retinoic acid binding protein II as a marker for breast cancer
EP1831696B1 (fr) Utilisation de la proteine asc comme marqueur du cancer colorectal
US20060257951A1 (en) Use of protein spee as a marker for breast cancer
US20060257950A1 (en) Use of protein UBC13 as a marker for breast cancer
WO2005040809A1 (fr) Utilisation de la proteine hnrnp-f en tant que marqueur pour le cancer du sein
WO2005124357A1 (fr) Utilisation de la proteine facteur d'elongation 1-alpha-1 comme marqueur pour le cancer du sein
WO2005124360A2 (fr) Utilisation d'une proteine tebp en tant que marqueur pour le cancer du sein
WO2005124354A2 (fr) Utilisation de proteine comme marqueur du cancer du sein
WO2005040805A1 (fr) Utilisation de la proteine masp en tant que marqueur pour le cancer du sein
WO2005040810A1 (fr) Utilisation de la proteine hnrnp-k comme marqueur du cancer du sein
WO2005040811A1 (fr) Utilisation de la proteine tip47 comme marqueur du cancer du sein
WO2005040808A1 (fr) Utilisation de la proteine fkbp52 en tant que marqueur du cancer du sein
WO2005040807A2 (fr) Utilisation de la proteine sws2 en tant que marqueur du cancer du sein
WO2005015220A1 (fr) Utilisation de la proteine crabp-i en tant que marqueur pour le cancer du sein
WO2005050217A1 (fr) Utilisation d'une phosphoserine phosphatase (pspase) proteique en tant que marqueur de cancer du sein
US20070218510A1 (en) Use of protein PSA3 as a marker for colorectal cancer
WO2005015222A1 (fr) Utilisation de la proteine de liaison a element amont eloigne (fuse) (fubp) comme marqueur du cancer colorectal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase